期刊文献+

坦索罗辛联合索利那新对改善良性前列腺增生致顽固性下尿路症状的疗效观察 被引量:3

Tamsulosin Combined with Solifenacin Improved the Intractable LUTS Caused by BPH Patients Significantly
下载PDF
导出
摘要 目的研究应用α受体阻滞剂坦索罗辛联合M受体阻滞剂索利拉新与单用α受体阻滞剂坦索罗辛对改善下尿路症状的疗效及安全性的差异。方法门诊108例前列腺增生有顽固性下尿路症状(lower urinary tract symptoms,LUTS)分别使用坦索罗辛(tamsulosin)和坦索罗辛配伍索利那新(solifenacin)治疗,进行对比观察。随机分为坦索罗辛联合索利拉新组55例(坦索罗辛0.2mg,1次/日,索利拉新5mg,1次/日),坦索罗辛组53例(坦索罗辛0.2mg,1次/日),均口服治疗4周。治疗前后分别进行国际前列腺储尿期症状评分(储尿期IPSS)、生活质量评分(QOL)和最大尿流率(Qmax)检测,评价两者对LUTS的治疗效果。结果坦索罗辛组IPSS、QOL评分分别由治疗前17.21±4.10、4.68±0.70,下降至15.82±5.50、4.50±0.70;Qmax由治疗前12.30±6.10ml/s,增加至14.20±8.51ml/s,其与治疗前相比差异不显著(P>0.05);坦索罗辛联合索利拉新组IPSS,QOL评分分别由治疗前18.43±5.11、4.55±0.92,下降至13.56±5.61、3.84±0.90,Qmax由治疗前11.40±6.90ml/s,增加至16.60±8.30ml/s,与治疗前相比差异明显(P<0.01)。联合用药组在同单纯使用坦索罗辛一样,均未见明显不良反应与严重合并症。结论坦索罗辛联合索利拉新治疗顽固性下尿路症状,特别是单一应用高选择性α受体阻滞剂如坦索罗辛治疗效果不佳者,可以明显改善下尿路症状,且无严重的并发症和不良反应发生,能有效地提高患者的生活质量。 Objective To study the efficacy and safety of using α receptor blocker (Tamsulosin) combined with M receptor blocker (Solifenacin) in improving the Lower Urinary Tract Symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) comparing with u- sing Tamsulosin singly. Methods We studied 108 Patients with complaints of intractable LUTS caused by BPH in random. 108 Patients were divided at random into two groups. Patients in the group of Tamsulosin combined with Solifenacin (55 cases) received a 4 - week course of once daily 0. 2mg tamsulosin and 5mg Solifenacin, while patients in the group of Tamsulosin (53 cases) received a 4 -week course of once daily 0.2mg tamsulosin singly. All patients were assessed using International Prostate Symptom Score (IPSS) , quality of life (QOL) Questionnaire and Qmax. Results Total IPSS and QOL decreased from 17.21±4.10,4.68±0.70 to 15.82±5.50,4.50±0.70 respectively in the group of Tamsulosin, and Qmax increased from 12.30±6.10ml/s to 14.20±8.51ml/s (P 〉 0. 05 ). In the group of Ta- msulosin combined with Solifenacin, total IPSS and QOL significantly decreased from 18.43±5.11,4.55±0.92 to 13.56±8.61,3.84±0.90 respectively, and in the group of Tamsulosin, Qmax increased from 11.40±6.90ml/s to 16.60±8.30ml/s( P 〈 0.01 ). Both groups showed no abvious side - effect and serious complications. Conclusion Combination of Tamsulosin and Solifenacin improved the intracta- ble LUTS caused by BPH,significantly and safely, especially a for the patients with single application of high - selective α - blockers such as tamsulosin poor treatment. It could significantly improve lower urinary tract symptoms and the patient's quality of life, and without seri- ous complications and side effects.
出处 《医学研究杂志》 2012年第12期77-79,共3页 Journal of Medical Research
基金 江苏省"六大人才高峰"基金资助项目(2005A2)
关键词 良性前列腺增生 下尿路症状 坦索罗辛 索利那新 Benign prostatic hyperplasia (BPH) Lower urinary tract symptoms (LUTS) Tamsulosin Solifenacin
  • 相关文献

参考文献7

二级参考文献36

  • 1龚隽,程文,高建平,张征宇,葛京平,周水根,周文泉,马宏青,魏武,薛松,徐振宇,王冬,许松.梗阻性不稳定膀胱模型的尿流动力学评价[J].医学研究生学报,2005,18(7):603-605. 被引量:1
  • 2程文,高建平,张征宇.梗阻性不稳定膀胱逼尿肌细胞内Ca^(2+)的变化及意义[J].医学研究生学报,2005,18(9):787-789. 被引量:3
  • 3Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function, report from the standardisaton subcommittee of the International Continence Society. Neurourol Urodyn, 2002, 21: 167-178.
  • 4Rovner ES, Wein AJ. Incidence and prevalence of overactive bladder. Curr Urol Rep, 2002, 3:434- 438.
  • 5Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int, 2006, 97: 96-100.
  • 6Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int, 2007, 100: 987-1006.
  • 7Ikeda K, Kobayashi S, Suzuki M, et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. N-S Arch Pharmacol, 2002, 366: 97-103.
  • 8Ohtake A, Ukai M, Hatanaka T, et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmaeol, 2004, 492:243- 250.
  • 9Kobayashi S, Ikeda K, Miyata K. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. Life Sci, 2004, 74: 843-853.
  • 10Smulders RA, Krauwinkel WJ, Swart PJ, et al. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol, 2004, 44:1023- 1033.

共引文献327

同被引文献29

  • 1蒋雨平,王坚,丁正同,邬剑军,陈嬿.原发性帕金森病的诊断标准(2005年)[J].中国临床神经科学,2006,14(1):40-40. 被引量:157
  • 2吴卫红,江波涛,邹伟,等.od受体阻滞剂联合M受体阻滞剂治疗前列腺电切术后下尿路症状的临床研究[J].中外健康文摘,2012,23(42):127-128.
  • 3孙莉,余舒扬.帕金森病伴发认知障碍患者非运动症状特点的研究[J].中华临床医师杂志(电子版),2013,11(11):4799-4805.
  • 4Sammour ZM,Gomes CM,Barbosa ER,et al.Voiding dysfunction in patients with Parkinson's disease:impact of neurological impairment and clinical parameters[J].Neurourol Urodyn,2009,28(6):510-515.
  • 5Swinburn P,Lloyd A,Ali S,et al.Preferences for antimuscarinic therapy for overactive bladder[J].BJU Int,2011,108(6):868-873.
  • 6Fernandes C,Hoyle E,Dempster E,et al.Performance deftcit of alpha7 nicotinic receptor knockout mice in a delayed matching-toplace task suggests a mild impairment of working/episodic-like memory[J].Genes Brain Behav,2006,5(6):433-440.
  • 7Greco KA,Mc Vary KT.The role of combination medical therapy in benigen prostatic hyperplasia[J].Int J Impot Res,2008,20(Suppl3):S33-S43.
  • 8孙祥宙,刘贵华,高勇,黄燕平,邓春华.盐酸特拉唑嗪联合酒石酸托特罗定治疗Ⅲ型前列腺炎40例[J].广东医学,2008,29(10):1611-1613. 被引量:8
  • 9姜亚卓,杜双宽,陈娟.坦索罗辛对前列腺电切术后生活质量的影响[J].临床泌尿外科杂志,2009,24(5):396-397. 被引量:2
  • 10孙元明,顾卫东,吕坚伟,冷静,薄隽杰,刘东明.联合应用坦索罗辛和托特罗定治疗男性顽固性下尿路症状的临床研究[J].中华男科学杂志,2010,16(9):790-793. 被引量:12

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部